The receptor gp130 is utilized by cytokines including interleukin 6, leukemia inhibitory factor, oncostatin M, cilary neurotrophic factor and cardiotrophin. It is essential for myocardial development and haematopoiesis during embryogenesis, and its role as a 
Introduction
Gp130 is a transmembrane receptor required for signal transduction by the neuropoietic family of cytokines, and is involved in a broad range of biological activities that includes stimulation of haematopoietic cells, development of neuronal cells and myocardial development (reviewed in Kishimoto et al., 1995) . The role of these growth factors and receptors in development, repair and disease has generated intense interest in the mechanism by which cytokine binding to a membrane bound receptor induces an intracellular response. Gp130 is expressed in almost all organs and targeted inactivation of the gp130 gene results in prenatal death from a variety of factors including defects in cardiac and haematological function (Yoshida et al., 1996) while elevated activation results in cardiac hypertrophy in the mouse (Hirota et al., 1995) . Gp130 mediated signalling is also involved in the regulation of a wide variety of adult tissue systems including haemopoesis, nervous system, bone, heart, adipose tissue, testes, liver and muscle (reviewed in Kishimoto et al., 1995) .
The intracellular signalling pathways activated by ligand mediated homo-or hetero-dimerization of gp130 include activation of the receptor associated JAK/Tyk tyrosine kinases Boulton et al., 1994) , the STAT family of transcription factors (Stahl et al., 1995) and src-family tyrosine kinase pathways (Ernst et al., 1994) .
Gp130 was initially cloned as an essential transmembrane component for signalling mediated by interleukin 6 (IL-6) (Hibi et al., 1990) . Primary sequence comparison indicates that gp130 is a member of the haematopoietin receptor family (Cosman, 1993 ) with significant sequence homology to human granulocyte-colony stimulating factor receptor (G-CSF-R) (Hibi et al., 1990) . The extracellular region of gp130 is predicted to be composed of an amino terminal immunoglobulin-(Ig)-like domain (amino acid residues 1-97), a haematopoietin or cytokine-binding homology region (CHR) (residues 98-302), and three fibronectin type III repeats proximal to the membrane (Figure 1 ). The CHR domains have primary sequence elements conserved in nearly all members of the family including a carboxy terminal motif, Trp-Ser-XTrp-Ser. The X-ray crystal structure of the CHR domain of gp130 has recently been determined (Bravo et al., 1998) and has the same topology as related receptors i.e. growth hormone (de Vos et al., 1992) , interferon (Walter et al., 1995) , prolactin (Somers et al., 1994) and erythropoietin (EPO) (Livnah et al., 1996) . The structure is composed of two β barrel domains each consisting of seven anti-parallel β strands with an L-shaped quaternary structure. Loops from the barrels form a cytokine binding site between the two domains. Deletion studies of gp130 have revealed that the membrane distal half of the receptor, consisting of the Ig and CHR domains, is sufficient for the formation of a ternary complex with IL-6 and IL-6 receptor (Horsten et al., 1995) .
Signal transduction by IL-6 occurs via dimerization of gp130 (Murakami et al., 1993) following the formation of a hexameric complex containing two molecules of gp130, two molecules of IL-6 ligand and two molecules of a specific IL-6 receptor (Ward et al., 1994) . Gp130 is also required as a receptor for signalling mediated by neuropoietic cytokines which associate with a secondary transmembrane receptor, LIF-R (Gearing et al., 1991) . These include oncostatin M (OSM), interleukin-11 (IL-11) (Hilton et al., 1994) , cilary neurotrophic factor (CNTF) (Davis et al., 1993; Baumann et al., 1993) , leukemia inhibitory factor (LIF) (Gearing et al., 1992) and cardiotrophin 1 (CT-1) (Pennica et al., 1995) . OSM can also mediate signalling by heterodimerization of gp130 with a novel transmembrane signalling receptor, OSM-R (Mosley et al., 1996) .
Of the known neuropoietic cytokines, only OSM can bind directly to gp130 with an equilibrium dissociation constant (K D ) in the order of 10 -8 M (Gearing et al., 1992; Liu et al., 1992; Sporeno et al., 1994) . This property facilitates receptorligand interaction studies on this system compared with other members of the neuropoietic family which require additional proteins to bind gp130 with an equivalent affinity. Oncostatin M (OSM) is a heat and acid stable growth factor that was originally isolated from the serum-free supernatant of phorbol 12-myristate 13-acetate treated U937 histiocytic leukemia cells by its ability to inhibit the growth of the human melanoma cell line, A375 (Zarling et al., 1986) . OSM shares biological properties with other members of the neuropoietic family (Wallace et al., 1995) but is most closely related to LIF both in structure and function (Rose and Bruce 1991; Piquet et al., 1994) . In addition, the proximity of their respective genes on human chromosome 22 has led to the suggestion that they were formed by gene duplication (Giovannini et al., 1993; Rose et al., 1993) . The X-ray crystal structure of murine LIF belongs to the long chain subfamily of haematopoietin cytokines that have an up-up-down-down four helix bundle structure with each helix approximately 25 residues in length (Robinson et al., 1994) , and NMR studies on OSM indicate a similar high helical content with four major α-helices (Hoffman et al., 1996) .
Human OSM (hOSM) is expressed as a 28 kDa glycoprotein but the mature form has 33 C-terminal amino acids removed to produce a protein (OSM196) that has greater biological activity on responsive cells such as A375 (Bruce et al., 1992) .
Mutagenesis of the neuropoietic cytokines have identified receptor binding sites functionally equivalent to the sites I and II on GH and, in addition, a third site that includes the CD loop and N-terminus of the D helix. In IL-6, sites I and II are responsible for binding to the IL6Ra and gp130 respectively, while site III is recognized by a second gp130 receptor giving rise to the complex consisting of two IL-6, two IL-6Ra and two gp130 molecules Somers et al., 1997) .
For CNTF, sites I, II and III are proposed to be bound by CNTFR, gp130 and LIF-R respectively (Inoue et al., 1995; Panayotatos et al., 1995) . LIF also follows this three site model with sites I and II recognized by LIF-R and gp130 respectively and the third site being recognized by LIF-R .
Sequence analysis identifies a common protein sequence motif at site III that suggests a common role for this region among cytokines utilizing gp130 (Inoue et al., 1995) . Disruption of this site by mutagenesis leads to the loss of biological activity and the loss of LIF-R binding in the case of LIF. The similarities in the distribution of binding sites between the gp130 binding cytokines and growth hormone have led to the assumption that these cytokines function through a dimerization mechanism, with one cytokine molecule dimerizing two signalling receptors through distinct binding sites, but the interaction between gp130 and IL-6 is more sophisticated with additional ligand-receptor interactions playing a role in complex formation. These additional low affinity sites in receptor ligand interactions have been studied in the EPO and G-CSF systems (Philo et al., 1996; Horan et al., 1996) .
It has been proposed that the Ig-like and CHR domains interact with sites III and II respectively in IL-6 (Simpson et al., 1997) . The interactions of gp130 in heterodimerization with LIF-R or OSM-R are still unclear and it is difficult to reconcile the information available with a model consistent with the IL-6 complex.
To examine this issue we have expressed different combinations of gp130 domains and analysed their binding by surface plasmon resonance (SPR) to OSM196 and a panel of OSM analogues with alanine substitutions in the predicted site II and III regions. This approach allows the assignment of the receptor components to their receptor binding sites on the ligand. The results show a classical site II interaction on OSM for the CHR domain that contributes the majority of the binding energy, but in addition, a secondary interaction between the Ig and CHR domains (Ig-CHR) and site III. The implications for complex formation with the family of cytokines utilizing gp130 and their receptors are discussed.
Materials and methods
Cloning and expression of OSM U937 cells were grown to a density of 1.3ϫ10 6 cells/ml, induced with 10 ng/ml phorbal myristyl acetate (PMA) and incubated for 36 h. Poly(A) RNA fractions were purified by affinity chromatography on oligo(dT) cellulose. Poly(A) RNA was used as a template for cDNA synthesis with the OSM specific oligonucleotide primer (5Ј-CGCATCCTTCACCGGC-AAGG-3Ј). Second strand synthesis and amplification of the oncostatin M reading frame were achieved by PCR with the primers 5Ј-ATAGGATCCGCGGCTATAGGCAGCTGCTCG-AAAGAG-3Ј complimentary to nucleotides 76-102 of OSM cDNA with a BamHI site and 5Ј-GCGGAATTCCTACCG-GGGCAGCTGTCCCCTGGTCAT-3Ј.
The PCR product was cloned into EcoRI/BamHI digested pGEX-2T, and the DNA sequenced. A subclone consisting of the sequence encoding amino acid residues 1-196 and a rhinovirus 3C protease recognition sequence at the N-terminus of the OSM gene was constructed with appropriate PCR primers. hOSM196 was expressed as a glutathione-S-transferase (GST) fusion protein and purified as described previously for LIF except that the GST fusion protein was cleaved by a GST-3c protease fusion instead of thrombin (Robinson et al., 1994) .
Characterization of OSM
Biological activity of the OSM196 was determined by proliferation assays on the Ba/F3-hLIF-R/hgp130 cell line which expresses both human gp130 and LIF-R (Robinson et al., 1994) . The N-terminus was verified by amino acid sequencing. The molecular weight of the purified OSM was examined by gel exclusion on a Superdex 75 HR10/30 column (Pharmacia) equilibrated with phosphate buffered saline and run at 0.8 ml/ min. The results of the gel filtration were confirmed by sedimentation equilibrium analysis using an Optima XL-A analytical ultracentrifuge (Beckman Instruments). Samples (0.5 mg/ml) of OSM196 were dialysed separately against 20 mM MES pH 6.0, and 20 mM Tris-HCl pH 7.6. Dialysed samples and buffer controls were centrifuged in double sector 12 mm centrepieces up to 40 000 r.p.m. at 20°C. Protein sedimentation was monitored at 280 nm at various time points for each rotation speed. When equilibrium was established, an appropriate model was fitted to the experimental values of protein concentration gp130-OSM interactions against rotor radius to determine molecular weight according to the equation;
where v is the partial specific volume of the protein (0.727 ml/g for OSM196 at 25°C), ρ is the solution density and ω is the angular velocity.
Construction of a pIG-gp130-Fc plasmid that incorporates a protease cleavage site
This plasmid was identical to the previously described pIGgp130-Fc except that a recognition site for the Rhino virus 3c protease (Walker et al., 1994) was engineered between the coding regions of gp130 (residues 1-328) and IGg1 Fc. The inclusion of the 3c recognition site was achieved by the use of PCR overlap (Ho et al., 1989) , the sequence of the primers used is available on request.
Mutagenesis of pIG-gp130-Fc generated a five amino acid insertion between the first two residues (EP, amino acids in one letter code) of the IGg1 hinge region. Thus, this process created the seven residue recognition site of the 3c protease-EVLFQ/GP, where cleavage of this sequence by the 3c protease is indicated by the slash.
Expression and purification of soluble gp130
Soluble gp130 was expressed in human embryonal kidney cell line 293T using the modified pIG-gp130-Fc plasmid as described previously . The gp130-Fc protein was purified on protein-A Sepharose (Pharmacia) and the Ig-CHR portion released by a GST-3c protease fusion protein as described earlier (Karow et al., 1996) .
Construction of mutant human oncostatin-M expression plasmids
As for wild type OSM, all DNA sequences coding for OSM mutants were cloned into the version of the pGEX plasmid modified to include a recognition site for the rhino virus 3c site. DNA sequences encoding mutant OSM molecules were created by PCR overlap (Ho et al., 1989) , using pGEX-3c-OSM and specific oligonucleotides for each individual mutant, the sequence of the primers used are available on request. The nucleotide sequences of all mutant constructs was verified by DNA sequencing using an ABI prism dye terminator cycle sequencing kit to perform the reactions, and analysis of the reactions on an ABI 373 sequencer.
Expression of human oncostatin-M mutants
Wild type and mutant OSM proteins were produced in an identical manner, essentially as previously described for human LIF except that a poly-histidine tagged version of the Rhino virus 3c protease was used to cleave OSM from the GST fusion protein. Conditions for cleavage were identical to those used by others (Walker et al., 1994) .
Construction, expression and purification of a poly-histidine tagged version of the Rhino virus 3c protease
The DNA sequence for the Rhino virus 3c protease was amplified by PCR and cloned into the BamHI/EcoRI site of the pTrcHis-A vector (Invitrogen). This construct codes for a 3c protease tagged at the N-terminus with six histidine residues (3c-his). Expression of the tagged 3c protease was performed according to manufacturer's instructions. Purification of the 3c-his was achieved by chromatography under non-denaturing 1095 conditions using Talon metal affinity resin (Clontech) following the manufacturer's protocol.
Numbering system for OSM and muteins
The pGEX plasmid modified to have a 3c protease site between the GST and OSM causes the addition of four residues at the N-terminus of OSM after cleavage of the fusion protein by 3c protease. However, the amino acid numbering of OSM used here remains the same as in wild type OSM (Malik et al., 1989) such that the ϩ1 residue is an alanine. Expression and purification of gp130 CHR domain PCR was used to amplify the region coding for amino acids 1-302 of the human gp130 and inserted into pHEN1 via NcoI and NotI sites. The DNA fragment encoding amino acids 97-302 and a C-terminal c-myc tag (amino acid sequence AAAEQKLISEEDLN) were subcloned into a pMALp2 3C vector. This vector was constructed from pMALp2 (New England Biolabs) with a linker consisting of the 3c protease cleavage site inserted into the XmnI and XbaI sites of the poly linker. The introduction of this linker introduced a new SmaI site and recreated the XbaI site allowing insertion of sub clones as blunt end/XbaI fragments. Escherichia coli strain HW1110 was transformed with the constructs and grown in 4 litres 2ϫTY, 0.3% glucose 100 µg/ml ampicillin, at 27°C in a New Brunswick Bioflo fermenter. Transformed cells were grown in 4 litres of 2ϫTY at 26°C to an OD 600nm of 2.0 and the expression of maltose binding protein (MBP) fusion protein induced by adding isopropylthiogalactoside to a final concentration of 0.2 mM. After incubation for 4 h the cells were pelleted and washed in a half volume of 20% (w/v) sucrose, 30 mM Tris-HCl pH 8.0 with gentle shaking. After centrifugation the cell pellet was washed with 5 mM MgSO 4 , 1 mM EDTA for 10 min on ice. The periplasmic fraction was recovered by centrifugation. The periplasmic preparations were passed over a FastFlow 100/300 Sepharose Q column equilibrated in 20mM Tris-HCl HCl pH 8.0 and protein fractions eluted with a linear gradient of 0 to 0.7 M NaCl, the MBP fusion eluting with 0.3 M NaCl. Fractions containing the fusion protein were identified by OSM binding activity, pooled and concentrated using YM-10 units (Amicon). The fusion was cleaved by GST-3c protease at 4°C for 2 h and the CHR domain separated from the MBP by passing through an amylose resin column (New England Biolabs). The CHR domain was finally purified by size exclusion chromatography on a TSK G3000SW 21 mm column equilibrated with phosphate buffered saline.
As with OSM196 the CHR domain protein was N-terminal sequenced, the molecular weight was determined by mass spectroscopy and gel exclusion chromatography using a TSK GS2000 column equilibrated with phosphate buffered saline pH 7.4.
Determination of protein concentrations
The concentrations of OSM196 and gp130 CHR domains were determined by a modified Bradford assay using Coomassie plus Protein Assay Reagent (Pierce) against standards for each protein that had been quantified by amino acid analysis.
Analysis of the receptor ligand interactions
The interactions of the cytokine receptor domains with immobilized OSM were analysed by surface plasmon resonance (SPR) using the BIAcore 2000 system as described by the manufacturer. Approximately 2000 RU (resonance units) of OSM was immobilized onto a CM5 sensor chip surface by amine or ligand thiol coupling according to the manufacturer's instructions. A flow cell on the same chip underwent the same process but without the presence of protein and was used as a control in subsequent experiments. The immobilization and binding assays were performed in 10 mM HEPES, pH 7.4, 0.15 M NaCl and 0.0005% surfactant P20 at a flow rate of 5 µl/min. The OSM and mutants were applied in 0.1 mg/ml in 10 mM sodium acetate pH 4.5. Receptor was passed over the flow cells at a flow rate of 1 µl/min and an injection volume of 50 µl for equilibrium analysis and 50 µl/min and an injection volume of 100 µl for the kinetic analysis. For the equilibrium analysis, six serial dilutions were made from an original concentration of 600 nM for CHR and 100 nM for the Ig-CHR domains. For the kinetic analysis, four serial dilutions were made from an original concentration of 100 nM for CHR and 20 nM for the Ig-CHR domains. For comparison of binding to the OSM muteins serial dilutions were made from 1 µM and 100 nM for the CHR and Ig-CHR domains respectively.
The OSM sensor surface was regenerated with 25 mM HCl for 30 s after receptor binding with only a very small loss in activity (a 4.7% decrease in maximum response of the OSM196 coupled sensor surface was recorded after 10 rounds of binding and regeneration). This allowed the same sensor surfaces to be used throughout the experiments. Sets of binding curves were analysed by the BIAevaluation 3.0 program using numerical integration of differential rate equations and global fitting (Karlsson and Falt, 1997) .
Results

Expression and purification of OSM
After cleavage of the GST fusion protein the purified OSM protein migrated as a homogeneous 22 kDa band during polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulphate (SDS-PAGE) (Figure 2a ). The N-terminal protein sequence of the purified protein was identified as GPGSAAIGS by direct sequencing on an Applied Biosystems 1096 automated gas phase sequencer. This is the expected sequence of the product with the Gly Pro as the remnants of the 3c cleavage site and the Gly Ser of the spacer sequence followed by the first residue of OSM. Time of flight laser desorption mass spectroscopy gave the molecular weight of the protein as 23 kDa which agrees with the predicted value from the protein sequence of 22.5 kDa. Gel filtration of the same sample at pH 7.4 gave a major peak corresponding to 24.5 kDa when compared with molecular weight standards and additional minor peaks corresponding to 45 and 69 kDa (Figure 3a) . This is consistent with a monomeric form as the predominant species, but with dimers and trimers of OSM giving rise to the minor peaks. Sedimentation equilibrium analysis curve fitting to an ideal two component model, indicates that the OSM existed as a monomer at pH 6.0 but with a small proportion (0.2% of the total protein) exhibiting a molecular weight of approximately 60 kDa. This component increased to 18% of the total protein present when the pH was raised to 7.5 in identical conditions, and results from aggregation of the cytokine at physiological pH (Figure 3b ). Aggregation in the mobile phase has important implications for SPR analysis as the ligand can bind to the immobilized receptor through more than one site and the observed dissociation rate will be the product of these individual interactions. This gives rise to a slower dissociation component compared with the monomer. Therefore OSM would be predicted to give a higher affinity for receptor when used as the mobile phase at physiological pH, compared with the same experiment with cytokine immobilized.
The biological activity of the purified protein, as measured by the proliferation of the Ba/F3-hLIF-R/hgp130 cell line was comparable to that of human LIF with an EC50 of 0.2 ng/ml. HepG2 cells that respond to OSM but not LIF gave an EC50 with the recombinant OSM of 2 ng/ml.
Expression and purification of CHR domain
The purified MBP gp130 CHR domain fusion protein migrates as homogeneous 75 kDa band on SDS-PAGE (Figure 2b ). On digestion with 3c protease, the CHR was separated from the MBP to give a band of 30 kDa compared with the molecular weight calculated from their protein sequence of 25.2 kDa. The identity of the protein was confirmed by N-terminal sequencing (GPGSSGLPPEF). Electrospray mass spectroscopy gave a MW of 25206.6Ϯ7 compared to the calculated mass of 25205.99. Gel filtration of the protein gave a single peak corresponding to a molecular weight of 30 kDa and we assume that this is the monomeric form of the receptor (Figure 3c ). This value is higher than expected but reflects the extended rather than globular structure of the protein.
Characterization of the CHR domain-OSM196 interaction
Biosensors with surface plasmon resonance detection have already been used to characterize the equilibrium constants for the interaction of biological molecules including the interaction between cytokines and their receptors (Cunningham and Wells, 1993; Ward et al., 1995; Myszka et al., 1996) . However the determination of an equilibrium constant from the ratio of kinetic rate measurements of adsorption and desorption is open to criticism of the relevance of the observed rate constants to the actual equilibrium constant (Schuck and Minton, 1996) . To address these points with the OSM196-gp130 interaction we compared the binding constants obtained from kinetic rate measurements with those from equilibrium measurements of the CHR domain binding to OSM196 immobilized by amine coupling to the sensor chip. In addition, binding constants were obtained from kinetic rate measurements of OSM196 coupled through amines, and a construct of OSM196 with an additional cysteine residue at the C-terminus coupled through a thiol linkage, and OSM196 binding to cytokine receptor domain immobilized on the sensor chip.
Comparison of the sensogram traces for the equilibrium analysis of the CHR domain binding to OSM confirm that a plateau response was obtained with a 50 µl injection volume for the concentration range 600 to 18 nM CHR domain and therefore reflected equilibrium between adsorbed receptor and the concentration of free receptor in the injected sample ( Figure  4a Table I ). The kinetic constants were determined by fitting globally a 1:1 model of receptor ligand interaction taking mass transport into account i.e.
A ϩ B ⇔ AB where A is the receptor in the mobile phase and B is the immobilized ligand.
Four sensograms of differing receptor concentrations (in the range 100 to 12.5 nM) were used in the analysis obtaining χ 2 ഛ 1.6 for the overall fit.
The value from measuring the kinetic constants from OSM196 binding to immobilized cytokine receptor domain gives values that are higher (16 nM) than the previous experiments, and gave a poorer fit to the simple 1:1 models of interaction (χ 2 ഛ 15). Given OSM196 tendency to aggregate, we believe these higher values are due to avidity rather than a true measure of the receptor-ligand interaction. Due to the instability of the OSM196 above pH 7.0 at room temperature, we were unable to perform competitive binding studies between OSM196 in the injected sample and immobilized OSM196 for the receptor binding site to determine an equilibrium constant in solution, but the agreement between the values obtained from the various experiments support the view that the equilibrium constants determined by kinetic rate constants of receptor binding to immobilized OSM196 are a measure of the true interaction. 
Characterization of the Ig-CHR domains/OSM196 interaction
To determine the equilibrium dissociation constant for Ig-CHR domains of gp130 by thermodynamics, an identical experiment was conducted using the larger receptor construct (Figure 4c ). It is obvious from the sensogram that equilibrium was not reached by the end of the injection (50 min). Although there is an initial fast on rate that is similar to the CHR domain, there is an additional component with a slower on rate that does not reach equilibrium before the end of the injection.
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The failure to reach equilibrium prevents a Scatchard analysis. A kinetic analysis of the interaction for the receptor concentrations 20 to 2.5 nM (Figure 5b ) gave sensograms that did not agree to a calculated 1:1 interaction (χ 2 ഛ 32.5). The same data was analysed assuming two parallel independent reactions, a bivalent analyte and a two state reaction model. For all three complex models the fit appears reasonable with values of 0.69, 1.4 and 0.68 respectively (Table II) . Parallel reactions can occur if the immobilized ligand is heterogeneous. The bivalent analyte model describes the binding of one receptor to one or two immobilized receptor molecules and takes co-operative effects into account i.e.
A ϩ B ⇔ AB AB ϩ B ⇔ AB2 A two state reaction indicates an isomerization event that gradually leads to a more stable complex between the receptor and ligand, i.e.
A ϩ B ⇔ AB ⇔ AB* Where AB* is the complex formed from AB by the isomerization. The possibility of Ig-CHR receptor dimerization accounting for the additional binding is unlikely as the RU max values (the calculated maximum response of the sensor surface in RUs) for both receptor constructs in this experiment are similar (1.7 and 2.3 kRU for CHR and Ig-CHR respectively) and dimerization of the larger construct should result in a RU max value approaching 5.0 kRU. A common feature of all these models is an initial interaction with a K D in the range 105 to 62 nM, and an additional binding component with a 10-fold slower off rate. Although this supports the assumption that the 1:1 model is not valid for the Ig-CHR domains, the experimental data is not conclusive in determining the mode of interaction between the receptor and OSM. To identify an appropriate model, the binding of receptor constructs against a panel of OSM variants was analysed.
Interaction of receptor domains with OSM196 and variants
In order to determine the recognition sites on OSM for the receptor constructs the kinetic rate measurements of cytokine receptor domain with and without the N-terminus Ig-like domain were made against a panel of immobilized OSM196 variants with alanine substitutions in predicted site II and III positions ( Figure 6 ).
The OSM196 variants were OSM FK (F160A, K163A), C helix (M113A, P116A, N117A, N123A) and A helix (Q16A, K19A, L23A, D26A). From sequence alignment of LIF with hOSM, structure-function studies of hLIF, and NMR assignments for OSM (Hoffman et al., 1996) , OSM FK is predicted 5 . Kinetic analysis of the interaction of (a) CHR (100 to 12.5 nM) and (b) Ig-CHR domains (25 to 3.0 nM) with immobilized OSM196. The association and dissociation rates were derived from the appropriate components of the sensogram curve by the BIAevaluation 3.0 software using numerical integration of differential rate equations and global fitting. The models used for analysis of the systems are indicated and the fitted curves are overlaid on the sensogram traces.
to have alanine substitutions at site III, and C and A helices at site II.
The results of the analysis are given in Table III and Figure 6 . As expected, the alanine substitutions in A and C helices affecting site II perturb the binding of both forms of the receptor with a 1000-fold reduction in binding to the CHR domain. Alanine substitutions in site III have little effect on CHR binding compared with wild type OSM. With the Ig-CHR construct more binding than the CHR domain to the wild type cytokine is exhibited. This additional binding is not observed with OSM FK and the binding kinetics on this cytokine are comparable between the two forms of the receptor, agreeing with a 1:1 model of interaction (χ 2 ഛ 0.9). The analysis of sensograms of the Ig-CHR domains binding to the wild type OSM requires a more complex model than 1:1 to fit the data, and the best fit was obtained with the two state model (χ 2 ഛ 0.5) and these values are given in Table III .
Discussion
The expression and purification of the CHR domain has allowed the identification of the minimal unit of gp130 required (Sporeno et al., 1994) but weaker than that observed for gp130 on the cell surface (K D ϭ 10 -9 M) (Gearing et al., 1992) . The CHR binding site on the cytokine consists of residues of the predicted A and C helices and resembles site II on growth hormone. This pattern for gp130 binding has also been observed in LIF and CNTF (Panayotatos et al., 1995) . An additional binding component with a 10-fold slower dissociation rate was observed with the Ig-like domain present. This component was abolished with the FK mutant, predicted to have alanine substitutions in site III, while binding by the CHR domain was unaffected (K D for Ig-CHR and CHR constructs binding to OSM FK are 72 and 31 nM respectively).
A parallel two site model for Ig-CHR binding can be discounted as this predicts that the second site will be bound with a nanomolar affinity independently of the site I interaction, and this is not observed with the A and C helices mutations. The bivalent model also predicts that the second site interaction can occur independently but that the second component of binding is a product of the affinities of the two sites and so the affinity of the isolated second site may be undetectable under these conditions. The two state reaction model predicts that the removal of the initial binding event will prevent the formation of the slower dissociation form and agrees with the mutation studies.
From the kinetic studies on the receptors and OSM mutants we propose an intermolecular interaction occurs between one receptor and two OSM molecules. This can be represented by the following scheme:
OSM II and OSM III represents immobilized oncostatin M bound at site II and III respectively. Step 1 represents binding by the CRH to site II and step 2 represents the interaction of the Ig domain with site III of a second, adjacent cytokine molecule. We believe that this is an inter-rather than an intramolecular event as the structures of gp130 CHR and related receptor complexes would not allow an interaction between an N-terminal Ig-like domain and a cytokine bound by the CHR domain of the same receptor (Bravo et al., 1998) . In our experimental conditions the sites are not independent, either through conformational change on step 1 or through a much lower affinity for site III compared with site II, and the binding occurs in a sequential manner.
Step 1, and therefore step 2, is prevented by removing site II from the cytokine (OSM A and C).
Step 2 can be abolished by removing the Ig domain from the receptor or by mutating site III of the cytokine. The slower dissociation rate of the Ig-CHR/OSM II OSM III complex gives rise to the increase in receptor binding although the maximum number of receptor molecules bound by the sensor surface will be the same for both constructs as this is determined by the availability of OSM site II.
The results of our experiments suggest that site III, as well as being the major binding epitope for LIF-R, also overlaps with a second gp130 binding site. An example of recognition between the same ligand surface and different receptors occurs with GH-R and prolactin receptor that both bind to overlapping sites on GH . However, the second site of OSM might be disrupted by differences in chemical modification between the wild type and mutant OSM during immobilization to the flow cell or by changes in local tertiary structure caused by the alanine substitutions.
The presence of two sites for gp130, occupying a similar positions to site II and III on a cytokine has been observed for IL-6 (Paonessa et al., 1995) . The most recently proposed model for the IL-6 complex has IL-6 binding IL-6R at site I and gp130 to site II. The Ig-like domain of gp130 in this trimer binds to site III of the IL-6 molecule in a second trimer giving rise to a hexameric complex (Sporeno et al., 1994; Simpson et al., 1997) . A similar pattern is observed with CNTF where gp130 can associate with two CNTF-CNTF-R complexes and then with LIF-R to form a complex consisting of one gp130, one LIF-R, two CNTF and two CNTF-R gp130-OSM interactions molecules . However, a heterotrimeric complex of LIF with its receptor subunits has been characterized consisting of one molecule each of LIF, LIF-R and gp130 (Zhang et al., 1997) . All these complexes involve gp130 recognition of site II of the cytokine (Ciapponi et al., 1995; Paonessa et al., 1995; Panayotatos et al., 1995; Hudson et al., 1996) . Receptor interactions via site III is a general feature of the IL-6 family of cytokines and while there is little homology between the putative site II sequences recognized by gp130, there is a motif in the site III region or D1 cap region that follows the consensus sequence of Ø (Phe or Trp) (Glu or Gln) (Lys or Arg)2 Ø Xaa Gly (Ø, hydrophobic residue; Xaa, any residue) (Bazan 1991) . In LIF, OSM and CNTF, this region is recognized by LIF-R, and the mutation of residues to alanine reduces its affinity for this receptor. The possibility of gp130 also binding to site III for cytokines using LIF-R is unexpected but allows a general pattern of complex formation to be proposed for those systems involving gp130. As Figure  7 illustrates, a general pattern of complex formation can be generated from a symmetrical arrangement, with gp130 interactions with site II as the basis and interactions with site III varying between complexes. The extremes of this situation are the IL-6 complex with each ligand-gp130 complex crosslinking to each other through the site III interaction to give a hexamer, and the LIF complex where there is no viable gp130 site III interaction resulting in a heterotrimer. We suggest that CNTF and OSM are intermediate forms with signalling involving heterodimerization of receptors as with LIF but in a pseudosymmetrical arrangement similar to IL-6. In the case of OSM there are no additional cytokine specific recognition receptors found in the IL-6 and CNTF systems. Although the similarity between IL-6 and OSM in their interactions with gp130 would suggest that OSM could dimerize gp130 on the cell surface, no biological activity has been observed on Ba/F3 cells transfected with gp130 alone (K.R. Hudson, unpublished results) . The geometry or kinetics of association for the complex would appear to require the presence of LIF-R or OSM-R for intracellular signalling. An obvious problem in such an arrangement is the competition between receptors for site III. The two state model requires site II of OSM bound by gp130 before site III, while LIF-R can bind directly to site III (K. Hudson personal communication) . Another requirement for the proposed receptor complexes are additional cytokine binding sites on LIF-R and these have been reported (Owczarek et al., 1993; Layton et al., 1994; Fig. 7 . Schematic diagram of the proposed complex assembly for cytokines utilizing gp130. The immunoglobulin (Ig)-like and the CHR domains of gp130 are shown in green with the long chain helix bundle represented by the orange cylinder. The three receptor binding sites (I involving residues from helices A and D; II, A and C; and III, residues at the N-terminus of helix D) are illustrated with gp130 binding to site II. Various complexes involving this receptor-cytokine interaction are represented. For IL-6 the basic interaction has an additional receptor, IL-6R (yellow), bound to site I. Two of these complexes are crosslinked through an interaction between the gp130 Ig-like domains and the IL-6 site III, giving rise to a hexamer and intracellular homodimerization of the two gp130 receptors. For CNTF, the arrangement is the same as for IL-6 except that site I is now occupied by CNTF-R (yellow) and one of the gp130 receptors has been replaced by LIF-R (blue) binding to site III. This hexamer allows intracellular heterodimerization of the gp130 and LIF-R. The OSM complex is identical to that for CNTF except that there are no additional receptors bound to site I. A second cytokine molecule is bound through site III to the gp130 receptor and through additional sites on LIF-R or OSM-R. For LIF there is no gp130 site III interaction and the trimeric complex is formed with the predominant binding of LIF-R to site III and gp130 to site II. Robinson et al., 1994; Hudson et al., 1996) . A combination of receptor-receptor and receptor-ligand interactions could contribute to the creation of a second cytokine binding site.
The G-CSF-R interactions with its ligand may be relevant to gp130 as there is a 27.3% identity when the full length amino acid sequences of the receptors are compared. In G-CSF-R there are two binding sites for the ligand, one in the classical cytokine receptor domain and the second composed of the immunoglobulin-like domain and the N-terminal half of the cytokine receptor domain (Hiraoka et al., 1995) . Both sites in G-CSF-R are capable of interacting directly with the G-CSF with the secondary site having a K D of approximately 10 -8 M.
Although the exact process of complex formation is unclear, the role of the second site in G-CSF-R appears to allow the formation of a signal transducing receptor cytokine complex after the initial binding of the G-CSF to the receptor via the CHR domain. With OSM and gp130 this secondary interaction is predicted to be much weaker, and would not allow the formation of a viable signalling complex without additional interactions to hold the complex together. We propose the presence of two distinct binding sites on OSM for gp130 and that these secondary interactions contribute towards the binding of an additional cytokine molecule in an analogous manner to that proposed for IL-6 giving rise to a complex consisting of one gp130, one LIF-R or OSM-R and two cytokine molecules, with the receptors occupying symmetrically related positions in the complex. The SPR analysis of receptor binding to immobilized OSM will allow the identification of receptor residues involved in these binding interfaces and the receptor mutants will help in dissecting the assembly processes of supramolecular complexes involving gp130. Just as the presence of gp130 in receptor complexes explained the overlap in biological function of diverse but structurally related cytokines, so the interactions of gp130 with its ligands may provide a general scheme for the formation of these signal transducing complexes.
